Commonwealth Bank Share Price in Focus Ahead of A$2.35 Dividend as CBA Outpaces ASX 200

March 29, 2026
Commonwealth Bank Share Price in Focus Ahead of A$2.35 Dividend as CBA Outpaces ASX 200

SYDNEY, March 30, 2026, 02:12 AEDT

Commonwealth Bank of Australia shares could draw attention again on Monday, with the stock last finishing up 0.26% at A$173.63 on the Australian Securities Exchange—outperforming the broader market on Friday. Investors are eyeing an A$2.35 interim dividend as well.

Timing is key here: CBA stands as Australia’s largest listed bank, sporting a market value near A$288 billion, and its shares are still often seen as a safe harbor when markets get rocky. But on Friday, global stocks took a hit. Brent crude topped US$112 per barrel, putting that defensive play under pressure.

The fully franked payout hits accounts Monday, offering tax credits to plenty of Australian investors. It follows the Reserve Bank of Australia’s move to lift the cash rate to 4.1%. CBA, meanwhile, announced a 25 basis point increase to variable home-loan rates, effective March 27.

Friday saw fairly stable action. CBA shares bounced from A$172.17 up to A$174.29, with around 1.48 million shares changing hands. The 52-week spread runs from A$140.21 to A$192.00—shares are far from the bottom, though they haven’t returned to the high.

Westpac added 0.69% to close at A$40.74 on Friday, while ANZ gave up 0.44% to A$36.49. NAB ended down 1.34% at A$41.99. The ASX 200 staged a late bounce but finished just below flat for the session. Still, ABC noted the index closed out the week with a 1% loss, as concerns over the Middle East continued to weigh on sentiment.

CBA is still riding on February’s numbers. For the six months ending Dec. 31, 2025, the bank delivered a record first-half cash profit—its key metric—of A$5.45 billion, topping Visible Alpha’s analyst consensus of A$5.19 billion. Stronger positions in home and business lending, plus deposits, underpinned the result. Shares surged up to 8.4% that session. The interim dividend holds steady at A$2.35, with payment still to come.

The RBA’s rate hike this month drew a quick reaction from Commonwealth Bank’s Belinda Allen, who noted, “the domestic data flow alone justified a rate hike today.” In a separate comment, CBA’s retail banking chief Angus Sullivan flagged that “interest rate changes can put additional pressure on household budgets.” So, you’ve got stronger lending income on one side and pinched households on the other; that tension is right at the core of the current stock narrative. Reuters

CBA’s lofty valuation could come under more pressure if the oil shock keeps stoking inflation and puts the brakes on economic growth. Just last week, RBA Assistant Governor Christopher Kent flagged the threat that a drawn-out conflict poses to growth and inflation expectations. VanEck’s Russel Chesler pointed to Gulf-war volatility and uncertainty as “in the front seats”. Reuters

Caution still lingers. As of March 5, CBA held an Underperform call—the consensus from 14 analysts, according to Reuters stock data—even after delivering record half-year earnings. Now the focus turns to Monday: can the dividend and CBA’s recent show of strength help the stock hold firmer than the wider market once trading picks back up?

Stock Market Today

  • ASX Small-Cap Aroa Biosurgery Eyes 75% Upside on Strong FY26 Results
    May 26, 2026, 8:02 PM EDT. Aroa Biosurgery (ASX: ARX) posted robust FY26 results with NZ$104 million revenue, exceeding guidance and marking 23% growth from FY25. The company's Myriad product revenue surged 54%, driving momentum alongside operating cash flow improvements. Management expects FY27 revenue to grow 13-23%, backed by new product Symphony and expanded US direct sales. Broker Bell Potter highlighted Aroa's shift to a scalable sales model, boosting growth potential despite anticipated near-term cost rises. They assigned a $1.09 price target, implying around 75% upside from the current ASX price of 62 cents.